SHENVIROPAD outperforms pharmaceutical manufacturers in Menstruation-Related Symptom (MRS) solution due to its 99.0% significance in treating primary dysmenorrhea, much higher than all available medicine, for example, Ibuprofen NSAID with 50-70% significance for cramps.

SHENVIROPAD also tops all available Complementary and Alternative Medicine (CAMs) for primary dysmenorrhea in efficacy, convenience, manageability, safety, and wellness development.